51
|
Sada KE, Hayashi K, Asano Y, Katayama Y, Hiramatsu Asano S, Ohashi K, Morishita M, Watanabe H, Narazaki M, Matsumoto Y, Yajima N, Yoshimi R, Shimojima Y, Ono S, Kajiyama H, Ichinose K, Sato S, Fujiwara M, Wada J. AB0387 TREATMENT STATUS FOR OSTEOPOROSIS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: CROSS-SECTIONAL ANALYSIS FROM A LUPUS REGISTRY OF NATIONWIDE INSTITUTIONS (LUNA). Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Osteoporosis is one of the most important adverse effects of glucocorticoids in patients with systemic lupus erythematosus (SLE). Because osteoporosis is accelerated by chronic kidney disease (CKD), more attention should be paid to the treatment for osteoporosis in SLE patients with CKD. Many treatment options for osteoporosis have emerged recently, but treatment status in patients with SLE is not elucidated.Objectives:The purpose of this study is to elucidate the treatment status for osteoporosis in patients with SLE among the CKD stages.Methods:Using data from lupus registry of nationwide institutions (LUNA), a cross-sectional analysis was performed. We firstly described treatment status for osteoporosis in all enrolled patients. Secondary, treatment status for osteoporosis was compared among CKD stages. Finally, bone damage in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) was compared among CKD stages.Results:The median age (interquartile range [IQR]) of enrolled 917 patients was 44 (34- 57) years and 809 patients (88%) were female. CKD stages were follows: CKD stage 1, 234 (26%); CKD stage 2, 465 (51%); CKD stage 3, 189 (21%); CKD stage 4, 9 (1%); CKD stage 5, 16 (2%). Median (IQR) age, female sex, and median (IQR) previous maximum dose of prednisolone in patients with and without CKD (≥CKD stage 3) were 56 (46.5-66) and 41 (32-50), 191 (89%) and 615 (88%), and 40 (30-60) and 40 (30-55) mg/day, respectively. Bisphosphonate was administered in 388 (42%) patients, vitamin D supplements in 448 (49%), Ca supplements in 36 (4%), denosumab in 20 (2%) and teriparatide in 14 (2%), respectively. Of enrolled patients, any treatment for osteoporosis was not administered in 226 (25%) patients. In spite of more frequent bone damage in patients with CKD compared to those without CKD (15% vs 10%, p=0.036), treatment status did not differ between patients with and without CKD (bisphosphonate: 41% vs 46%, p=0.29; vitamin D supplements: 50% vs 44%, p=0.14).Conclusion:About a quarter of patients with SLE did not take any treatment for osteoporosis. Treatment for osteoporosis might be strengthened to prevent bone damage in SLE patients with CKD.Disclosure of Interests:KEN-EI SADA Speakers bureau: I received speaker’s fee from GSK and Astra Zeneca K.K., Keigo Hayashi: None declared, Yosuke ASANO: None declared, Yu Katayama: None declared, Sumie Hiramatsu Asano: None declared, Keiji Ohashi: None declared, Michiko Morishita: None declared, Haruki Watanabe: None declared, Mariko Narazaki: None declared, Yoshinori Matsumoto: None declared, Nobuyuki Yajima: None declared, Ryusuke Yoshimi: None declared, Yasuhiro Shimojima: None declared, Shigeru Ono: None declared, Hiroshi Kajiyama: None declared, Kunihiro Ichinose: None declared, Shuzo Sato: None declared, Michio Fujiwara: None declared, Jun Wada: None declared
Collapse
|
52
|
Igawa T, Ichinose K, Okamoto M, Takatani A, Yajima N, Sada KE, Yoshimi R, Shimojima Y, Ono S, Kajiyama H, Sato S, Fujiwara M, Kawakami A. AB0413 INVESTIGATION OF THE ASSOCIATION OF CARDIOVASCULAR EVENTS AND ANTI- SS-A ANTIBODIES AS RISK OF DEVELOPMENT IN PATIENTS WITH LUPUS NEPHRITIS FROM THE LUNA REGISTRY: A CROSS-SECTIONAL STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.4047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Cardiovascular disease(CVD) has been identified as a major cause of morbidity and mortality in patients with lupus nephritis(LN)1) 2). There is a clear causal relationship between the onset of neonatal lupus (cardiac complications) and SS-A antibodies3) 4), but no association has been reported in adults. In recent years, there have been reports from overseas that suggest the association between CVD and anti-SS-A antibody in adult systemic lupus erythematosus (SLE) patients5) 6). So far, no studies have not been reported to evaluate the relationship between anti-SS-A antibody and the risk of developing CVD in LN in a large cohort of patients with SLE in Japan.Objectives:The aim of this study was to evaluate the association between anti-SS-A antibody and the risk of developing CVD in LN patients using a multicenter registration study [Lupus registry of nationwide institution (LUNA)] in Japan.Methods:We identified 931 patients diagnosed with SLE in the Lupus registry of nationwide institution (LUNA), and further identified 275 LN patients with known the presence or absence of both development of CVD and presence of anti-SS-A antibody. We defined the exposure factor as anti-SS-A antibody, and the outcome as CVD. SELENA-SLEDAI score (at diagnosis), eGFR <60%, HbA1c, BMI, and steroid pulse treatment history were used as confounding factors and we analyzed using logistic regression analysis.Results:We found 68 patients (24.7%) complicated with CVD, including percarditis (7.3%), cerebrovascular disorder (6.2%), peripheral Arterial Disease (6.2%), Ischemic heart disease (2.9%),venous thromboembolism (2.9%),pulmonary hypertension (1.5%), vulvular heart disease (1.1%), and cardiomyopathy (0.4%). In univariate analysis, there was no significant difference in the occurrence of CVD depending on the presence or absence of anti-SS-A antibody (p = 0.32), and the results of multivariate analysis showed no significant difference in anti-SS-A antibody [p = 0.23, odds: 0.41, 95% confidence interval (0.09-1.89)].Conclusion:The association between anti-SS-A antibody and the development of CVD in LN patients in Japan has not been identified.References:[1]Lupus. 2000;9(3):166-9[2]Arthritis Rheum.2019 Mar;71(3):403-410,[3]J Intern Med 265:653-662, 2009[4]Nat Clin Pract Rheumatol 5:139-148, 2009[5]Ann Rheum Dis 1990;49:627-629[6]Chest. 2018 Jan;153(1):143-151. Doi:Disclosure of Interests:None declared
Collapse
|
53
|
Ohata Y, Takeyari S, Nakano Y, Kitaoka T, Nakayama H, Bizaoui V, Yamamoto K, Miyata K, Yamamoto K, Fujiwara M, Kubota T, Michigami T, Yamamoto K, Yamamoto T, Namba N, Ebina K, Yoshikawa H, Ozono K. Correction to: Comprehensive genetic analyses using targeted next-generation sequencing and genotype-phenotype correlations in 53 Japanese patients with osteogenesis imperfecta. Osteoporos Int 2020; 31:1185. [PMID: 32246166 PMCID: PMC7237517 DOI: 10.1007/s00198-020-05396-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
The original article has been corrected.
Collapse
Affiliation(s)
- Y Ohata
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
| | - S Takeyari
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
| | - Y Nakano
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
| | - T Kitaoka
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
| | - H Nakayama
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
- The Japan Environment and Children's Study, Osaka Unit Center, Suita, Japan
| | - V Bizaoui
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
- Department of Medical Genetics, Reference Center for Skeletal Dysplasia, Hôpital Necker - Enfants Malades, Paris, France
| | - K Yamamoto
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
- Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan
| | - K Miyata
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
| | - K Yamamoto
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
- Department of Pediatrics, National Hospital Organization Osaka National Hospital, Osaka, Japan
| | - M Fujiwara
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
- The First Department of Oral and Maxillofacial Surgery, Osaka University Graduate School of Dentistry, Suita, Japan
| | - T Kubota
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
| | - T Michigami
- Department of Bone and Mineral Research, Osaka Women's and Children's Hospital, Izumi, Japan
| | - K Yamamoto
- Department of Pediatric Nephrology and Metabolism, Osaka Women's and Children's Hospital, Izumi, Japan
| | - T Yamamoto
- Department of Pediatrics, Minoh City Hospital, Minoh, Japan
| | - N Namba
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
- Department of Pediatrics, Osaka Hospital, Japan Community Healthcare Organization (JCHO), Osaka, Japan
| | - K Ebina
- Department of Musculoskeletal Regenerative Medicine, Osaka University Graduate School of Medicine, Suita, Japan
| | - H Yoshikawa
- Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan
| | - K Ozono
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan.
| |
Collapse
|
54
|
Fujiwara M, Komai Y, Yuasa T, Numao N, Yamamoto S, Fukui I, Yonese J. Pembrolizumab for a patient with metastatic castration-resistant prostate cancer with microsatellite instability-high. IJU Case Rep 2020; 3:62-64. [PMID: 32743472 PMCID: PMC7292086 DOI: 10.1002/iju5.12144] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2019] [Accepted: 01/22/2020] [Indexed: 01/21/2023] Open
Abstract
INTRODUCTION We report the case of a patient with metastatic castration-resistant prostate cancer with microsatellite instability-high who was treated with pembrolizumab after cabazitaxel administration. CASE PRESENTATION A 58-year-old patient with heavily pretreated metastatic castration-resistant prostate cancer, whose prostate surgical specimen was disclosed as microsatellite instability-high, underwent pembrolizumab therapy. After initiation of pembrolizumab, his prostate-specific antigen level decreased, imaging findings showed good response with lymph node shrinkage, and his walking difficulty decreased dramatically. CONCLUSION The rarity of microsatellite instability-high tumor in castration-resistant prostate cancer may hamper pembrolizumab administration. This potentially active agent should be considered as part of a treatment regimen for patients with microsatellite instability-high castration-resistant prostate cancer. To the best of our knowledge, this is the first report of a Japanese castration-resistant prostate cancer patient who demonstrated clinical benefit from pembrolizumab treatment.
Collapse
Affiliation(s)
- Motohiro Fujiwara
- Department of UrologyCancer Institute HospitalJapanese Foundation for Cancer ResearchTokyoJapan
| | - Yoshinobu Komai
- Department of UrologyCancer Institute HospitalJapanese Foundation for Cancer ResearchTokyoJapan
| | - Takeshi Yuasa
- Department of UrologyCancer Institute HospitalJapanese Foundation for Cancer ResearchTokyoJapan
| | - Noboru Numao
- Department of UrologyCancer Institute HospitalJapanese Foundation for Cancer ResearchTokyoJapan
| | - Shinya Yamamoto
- Department of UrologyCancer Institute HospitalJapanese Foundation for Cancer ResearchTokyoJapan
| | - Iwao Fukui
- Department of UrologyCancer Institute HospitalJapanese Foundation for Cancer ResearchTokyoJapan
| | - Junji Yonese
- Department of UrologyCancer Institute HospitalJapanese Foundation for Cancer ResearchTokyoJapan
| |
Collapse
|
55
|
Okabe N, Fujiwara M, Mochizuki M, Ohtsuka K, Nishigaya Y, Kobayashi Y, Kamma H. CD34-positive uterine lipoleiomyoma in a postmenopausal woman with chronic glomerulonephritis. EUR J GYNAECOL ONCOL 2019. [DOI: 10.12892/ejgo4661.2019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
56
|
Ohata Y, Takeyari S, Nakano Y, Kitaoka T, Nakayama H, Bizaoui V, Yamamoto K, Miyata K, Yamamoto K, Fujiwara M, Kubota T, Michigami T, Yamamoto K, Yamamoto T, Namba N, Ebina K, Yoshikawa H, Ozono K. Comprehensive genetic analyses using targeted next-generation sequencing and genotype-phenotype correlations in 53 Japanese patients with osteogenesis imperfecta. Osteoporos Int 2019; 30:2333-2342. [PMID: 31363794 PMCID: PMC7083816 DOI: 10.1007/s00198-019-05076-6] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/12/2019] [Accepted: 06/26/2019] [Indexed: 12/21/2022]
Abstract
UNLABELLED To elucidate mutation spectrum and genotype-phenotype correlations in Japanese patients with OI, we conducted comprehensive genetic analyses using NGS, as this had not been analyzed comprehensively in this patient population. Most mutations were located on COL1A1 and COL1A2. Glycine substitutions in COL1A1 resulted in the severe phenotype. INTRODUCTION Most cases of osteogenesis imperfecta (OI) are caused by mutations in COL1A1 or COL1A2, which encode α chains of type I collagen. However, mutations in at least 16 other genes also cause OI. The mutation spectrum in Japanese patients with OI has not been comprehensively analyzed, as it is difficult to identify using classical Sanger sequencing. In this study, we aimed to reveal the mutation spectrum and genotype-phenotype correlations in Japanese patients with OI using next-generation sequencing (NGS). METHODS We designed a capture panel for sequencing 15 candidate OI genes and 19 candidate genes that are associated with bone fragility or Wnt signaling. Using NGS, we examined 53 Japanese patients with OI from unrelated families. RESULTS Pathogenic mutations were detected in 43 out of 53 individuals. All mutations were heterozygous. Among the 43 individuals, 40 variants were identified including 15 novel mutations. We found these mutations in COL1A1 (n = 30, 69.8%), COL1A2 (n = 12, 27.9%), and IFITM5 (n = 1, 2.3%). Patients with glycine substitution on COL1A1 had a higher frequency of fractures and were more severely short-statured. Although no significant genotype-phenotype correlation was observed for bone mineral density, the trabecular bone score was significantly lower in patients with glycine substitutions. CONCLUSION We identified pathogenic mutations in 81% of our Japanese patients with OI. Most mutations were located on COL1A1 and COL1A2. This study revealed that glycine substitutions on COL1A1 resulted in the severe phenotype among Japanese patients with OI.
Collapse
Affiliation(s)
- Y Ohata
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
| | - S Takeyari
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
| | - Y Nakano
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
| | - T Kitaoka
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
| | - H Nakayama
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
- The Japan Environment and Children's Study, Osaka Unit Center, Suita, Japan
| | - V Bizaoui
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
- Department of Medical Genetics, Reference Center for Skeletal Dysplasia, Hôpital Necker - Enfants Malades, Paris, France
| | - K Yamamoto
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
- Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan
| | - K Miyata
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
| | - K Yamamoto
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
- Department of Pediatrics, National Hospital Organization Osaka National Hospital, Osaka, Japan
| | - M Fujiwara
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
- The First Department of Oral and Maxillofacial Surgery, Osaka University Graduate School of Dentistry, Suita, Japan
| | - T Kubota
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
| | - T Michigami
- Department of Bone and Mineral Research, Osaka Women's and Children's Hospital, Izumi, Japan
| | - K Yamamoto
- Department of Pediatric Nephrology and Metabolism, Osaka Women's and Children's Hospital, Izumi, Japan
| | - T Yamamoto
- Department of Pediatrics, Minoh City Hospital, Minoh, Japan
| | - N Namba
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
- Department of Pediatrics, Osaka Hospital, Japan Community Healthcare Organization (JCHO), Osaka, Japan
| | - K Ebina
- Department of Musculoskeletal Regenerative Medicine, Osaka University Graduate School of Medicine, Suita, Japan
| | - H Yoshikawa
- Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan
| | - K Ozono
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan.
| |
Collapse
|
57
|
Fujiwara M, Tsutani Y, Mimae T, Miyata Y, Okada M. P1.17-01 Surgical Outcome of Early Stage Lung Cancer Related vs Unrelated to Honeycomb Lesions with Interstitial Pneumonia. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
58
|
Toide M, Yokoyama M, Fujiwara M, Kijima T, Saito K, Fujii Y. Renal function after bladder-preserving therapy for patients with muscle-invasive bladder cancer: Results of selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induction chemoradiotherapy and partial cystectomy. Int J Urol 2019; 26:1010-1012. [PMID: 31284327 DOI: 10.1111/iju.14054] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Masahiro Toide
- Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan
| | - Minato Yokoyama
- Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan
| | | | - Toshiki Kijima
- Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan
| | - Kazutaka Saito
- Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan
| | - Yasuhisa Fujii
- Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan
| |
Collapse
|
59
|
Sato B, Kanda M, Ito S, Teramoto H, Mochizuki Y, Ishigure K, Murai T, Asada T, Ishiyama A, Matsushita H, Tanaka C, Kobayashi D, Fujiwara M, Kodera Y. Proposal of optimal cut-off of preoperative serum tumor marker levels to predict postoperative recurrences of gastric cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
60
|
Fujiwara M, Kawamura N, Okuno T. Preoperative inferior vena cava filter implantation to prevent pulmonary fat embolism in a patient showing renal angiomyolipoma extension into the renal vein: A case report and literature review. J Rural Med 2018; 13:181-184. [PMID: 30546809 PMCID: PMC6288729 DOI: 10.2185/jrm.2976] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2018] [Accepted: 06/11/2018] [Indexed: 01/11/2023] Open
Abstract
Renal angiomyolipoma without local invasion is usually considered benign entity, however, it may extend into the renal vein or the inferior vena cava. Renal angiomyolipoma with venous extension should be treated; however, surgical complications such as iatrogenic pulmonary fat embolism remain a serious concern. We present a case of a 66-year-old Japanese woman without tuberous sclerosis in whom a right-sided renal tumor was incidentally detected on ultrasonography during a health check-up. Further evaluation showed that the tumor extended into the renal vein, and she was successfully treated using preoperative inferior vena cava filter placement and radical nephrectomy. An inferior vena cava filter can prevent catastrophic pulmonary fat embolism during nephrectomy.
Collapse
Affiliation(s)
| | | | - Tetsuo Okuno
- Department of Urology, JA Toride Medical Center, Japan
| |
Collapse
|
61
|
Yamane K, Hayashi Y, Fujii Y, Ueda Y, Morita Y, Miyake Y, Fujiwara M, Nagamoto Y, Mito S, Watari Y, Tamekiyo H, Okimoto T, Muraoka Y. P2636Comparison of the efficacy of balloon angioplasty or paclitaxel-coated balloon or stent implantation for in-stent restenosis based on analysis by optical coherence tomography. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p2636] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- K Yamane
- Akane Foundation Tsuchiya General Hospital, Hiroshima, Japan
| | - Y Hayashi
- Akane Foundation Tsuchiya General Hospital, Hiroshima, Japan
| | - Y Fujii
- Akane Foundation Tsuchiya General Hospital, Hiroshima, Japan
| | - Y Ueda
- Akane Foundation Tsuchiya General Hospital, Hiroshima, Japan
| | - Y Morita
- Akane Foundation Tsuchiya General Hospital, Hiroshima, Japan
| | - Y Miyake
- Akane Foundation Tsuchiya General Hospital, Hiroshima, Japan
| | - M Fujiwara
- Akane Foundation Tsuchiya General Hospital, Hiroshima, Japan
| | - Y Nagamoto
- Akane Foundation Tsuchiya General Hospital, Hiroshima, Japan
| | - S Mito
- Akane Foundation Tsuchiya General Hospital, Hiroshima, Japan
| | - Y Watari
- Akane Foundation Tsuchiya General Hospital, Hiroshima, Japan
| | - H Tamekiyo
- Akane Foundation Tsuchiya General Hospital, Hiroshima, Japan
| | - T Okimoto
- Akane Foundation Tsuchiya General Hospital, Hiroshima, Japan
| | - Y Muraoka
- Akane Foundation Tsuchiya General Hospital, Hiroshima, Japan
| |
Collapse
|
62
|
Fujiwara M, Matoba T, Koga J, Okahara A, Funamoto D, Nakano K, Tsutsui H, Egashira K. 2422Nanoparticle-mediated delivery of toll-like receptor 4 antagonist to monocytes and ischemic myocardium enhances cardioprotection against ischemia-reperfusion injury in mice. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.2422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- M Fujiwara
- Kyushu University Graduate School of Medical Sciences, Cardiovascular Medicine, Fukuoka, Japan
| | - T Matoba
- Kyushu University Graduate School of Medical Sciences, Cardiovascular Medicine, Fukuoka, Japan
| | - J Koga
- Kyushu University Graduate School of Medical Sciences, Cardiovascular Research, Development, and Translational Research, Fukuoka, Japan
| | - A Okahara
- Kyushu University Graduate School of Medical Sciences, Cardiovascular Medicine, Fukuoka, Japan
| | - D Funamoto
- Kyushu University Graduate School of Medical Sciences, Cardiovascular Research, Development, and Translational Research, Fukuoka, Japan
| | - K Nakano
- Kyushu University Graduate School of Medical Sciences, Cardiovascular Research, Development, and Translational Research, Fukuoka, Japan
| | - H Tsutsui
- Kyushu University Graduate School of Medical Sciences, Cardiovascular Medicine, Fukuoka, Japan
| | - K Egashira
- Kyushu University Graduate School of Medical Sciences, Cardiovascular Research, Development, and Translational Research, Fukuoka, Japan
| |
Collapse
|
63
|
Okahara A, Matoba T, Koga J, Fujiwara M, Funamoto D, Nakano K, Tsutsui H, Egashira K. P1270Nanoparticle-mediated simultaneous targeting of mitochondria and inflammatory monocytes protects the brain from ischemia-reperfusion injury in mice. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- A Okahara
- Kyushu University Graduate School of Medical Sciences, Cardiovascular Medicine, Fukuoka, Japan
| | - T Matoba
- Kyushu University Graduate School of Medical Sciences, Cardiovascular Medicine, Fukuoka, Japan
| | - J Koga
- Kyushu University Graduate School of Medical Sciences, Cardiovascular Research, Development, and Translational Research, Fukuoka, Japan
| | - M Fujiwara
- Kyushu University Graduate School of Medical Sciences, Cardiovascular Medicine, Fukuoka, Japan
| | - D Funamoto
- Kyushu University Graduate School of Medical Sciences, Cardiovascular Research, Development, and Translational Research, Fukuoka, Japan
| | - K Nakano
- Kyushu University Graduate School of Medical Sciences, Cardiovascular Research, Development, and Translational Research, Fukuoka, Japan
| | - H Tsutsui
- Kyushu University Graduate School of Medical Sciences, Cardiovascular Medicine, Fukuoka, Japan
| | - K Egashira
- Kyushu University Graduate School of Medical Sciences, Cardiovascular Research, Development, and Translational Research, Fukuoka, Japan
| |
Collapse
|
64
|
Fujiwara M, Anstadt EJ, Flynn B, Morse K, Ng C, Paczkowski P, Zhou J, Mackay S, Wasko N, Nichols F, Clark RB. Enhanced TLR2 responses in multiple sclerosis. Clin Exp Immunol 2018; 193:313-326. [PMID: 30043528 PMCID: PMC6150258 DOI: 10.1111/cei.13150] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2018] [Revised: 03/29/2018] [Accepted: 04/18/2018] [Indexed: 12/17/2022] Open
Abstract
The roles of the microbiome and innate immunity in the pathogenesis of multiple sclerosis (MS) remain unclear. We have previously documented abnormally low levels of a microbiome‐derived Toll‐like receptor (TLR)2‐stimulating bacterial lipid in the blood of MS patients and postulated that this is indicative of a deficiency in the innate immune regulating function of the microbiome in MS. We postulated further that the resulting enhanced TLR2 responsiveness plays a critical role in the pathogenesis of MS. As proof‐of‐concept, we reported that decreasing systemic TLR2 responsiveness by administering very low‐dose TLR2 ligands attenuated significantly the mouse model of MS, experimental autoimmune encephalomyelitis. Studies of Toll‐like receptor responses in patients with MS have been conflicting. Importantly, most of these investigations have focused on the response to TLR4 ligation and few have characterized TLR2 responses in MS. In the present study, our goal was to characterize TLR2 responses of MS patients using multiple approaches. Studying a total of 26 MS patients and 32 healthy controls, we now document for the first time that a large fraction of MS patients (50%) demonstrate enhanced responsiveness to TLR2 stimulation. Interestingly, the enhanced TLR2 responders include a significant fraction of those with progressive forms of MS, a subset of patients considered unresponsive to adaptive immune system‐targeting therapies. Our results suggest the presence of a pathologically relevant TLR2 related innate immune abnormality in patients with both relapsing–remitting and progressive MS. These findings may have significant implications for understanding the role of innate immunity in the pathogenesis of MS.
Collapse
Affiliation(s)
- M Fujiwara
- Departments of Immunology and Medicine, University of Connecticut School of Medicine, Farmington, CT, USA
| | - E J Anstadt
- Departments of Immunology and Medicine, University of Connecticut School of Medicine, Farmington, CT, USA
| | - B Flynn
- IsoPlexis, Branford, CT, USA
| | - K Morse
- IsoPlexis, Branford, CT, USA
| | - C Ng
- IsoPlexis, Branford, CT, USA
| | | | - J Zhou
- IsoPlexis, Branford, CT, USA
| | | | - N Wasko
- Departments of Immunology and Medicine, University of Connecticut School of Medicine, Farmington, CT, USA
| | - F Nichols
- Division of Periodontology, University of Connecticut School of Medicine and School of Dental Health, Farmington, CT, USA
| | - R B Clark
- Departments of Immunology and Medicine, University of Connecticut School of Medicine, Farmington, CT, USA
| |
Collapse
|
65
|
Kohri H, Shiu SH, Chang WC, Yanai Y, Ahn DS, Ahn JK, Chen JY, Daté S, Ejiri H, Fujimura H, Fujiwara M, Fukui S, Gohn W, Hicks K, Hosaka A, Hotta T, Hwang SH, Imai K, Ishikawa T, Joo K, Kato Y, Kon Y, Lee HS, Maeda Y, Mibe T, Miyabe M, Morino Y, Muramatsu N, Nakano T, Nakatsugawa Y, Nam SI, Niiyama M, Noumi H, Ohashi Y, Ohta T, Oka M, Parker JD, Rangacharyulu C, Ryu SY, Sawada T, Shimizu H, Strokovsky EA, Sugaya Y, Sumihama M, Tsunemi T, Uchida M, Ungaro M, Wang SY, Yosoi M. Differential Cross Section and Photon-Beam Asymmetry for the γ[over →]p → π^{-}Δ^{++}(1232) Reaction at Forward π^{-} Angles for E_{γ}=1.5-2.95 GeV. Phys Rev Lett 2018; 120:202004. [PMID: 29864366 DOI: 10.1103/physrevlett.120.202004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/24/2018] [Revised: 03/11/2018] [Indexed: 06/08/2023]
Abstract
Differential cross sections and photon-beam asymmetries for the γ[over →]p→π^{-}Δ^{++}(1232) reaction have been measured for 0.7<cosθ_{π}^{c.m.}<1 and E_{γ}=1.5-2.95 GeV at SPring-8/LEPS. The first-ever high statistics cross-section data are obtained in this kinematical region, and the asymmetry data for 1.5<E_{γ}(GeV)<2.8 are obtained for the first time. This reaction has a unique feature for studying the production mechanisms of a pure uu[over ¯] quark pair in the final state from the proton. Although there is no distinct peak structure in the cross sections, a non-negligible excess over the theoretical predictions is observed at E_{γ}=1.5-1.8 GeV. The asymmetries are found to be negative in most of the present kinematical regions, suggesting the dominance of π exchange in the t channel. The negative asymmetries at forward meson production angles are different from the asymmetries previously measured for the photoproduction reactions producing a dd[over ¯] or an ss[over ¯] quark pair in the final state. Advanced theoretical models introducing nucleon resonances and additional unnatural-parity exchanges are needed to reproduce the present data.
Collapse
Affiliation(s)
- H Kohri
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - S H Shiu
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
- Department of Physics, National Central University, Taoyuan City 32001, Taiwan
| | - W C Chang
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - Y Yanai
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - D S Ahn
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - J K Ahn
- Department of Physics, Korea University, Seoul 02841, Republic of Korea
| | - J Y Chen
- Light Source Division, National Synchrotron Radiation Research Center, Hsinchu 30076, Taiwan
| | - S Daté
- Japan Synchrotron Radiation Research Institute, Sayo, Hyogo 679-5143, Japan
| | - H Ejiri
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - H Fujimura
- Wakayama Medical College, Wakayama 641-8509, Japan
| | - M Fujiwara
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
- National Institutes for Quantum and Radiological Science and Technology, Tokai, Ibaraki 319-1195, Japan
| | - S Fukui
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - W Gohn
- Department of Physics, University of Connecticut, Storrs, Connecticut 06269-3046, USA
| | - K Hicks
- Department of Physics and Astronomy, Ohio University, Athens, Ohio 45701, USA
| | - A Hosaka
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - T Hotta
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - S H Hwang
- Korea Research Institute of Standards and Science (KRISS), Daejeon 34113, Republic of Korea
| | - K Imai
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195, Japan
| | - T Ishikawa
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - K Joo
- Department of Physics, University of Connecticut, Storrs, Connecticut 06269-3046, USA
| | - Y Kato
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya, Aichi 464-8602, Japan
| | - Y Kon
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - H S Lee
- Rare Isotope Science Project, Institute for Basic Science, Daejeon 34047, Korea
| | - Y Maeda
- Proton Therapy Center, Fukui Prefectural Hospital, Fukui 910-8526, Japan
| | - T Mibe
- High Energy Accelerator Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - M Miyabe
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - Y Morino
- High Energy Accelerator Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - N Muramatsu
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - T Nakano
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - Y Nakatsugawa
- High Energy Accelerator Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - S I Nam
- Department of Physics, Pukyong National University (PKNU), Busan 608-737, Republic of Korea
| | - M Niiyama
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - H Noumi
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - Y Ohashi
- Japan Synchrotron Radiation Research Institute, Sayo, Hyogo 679-5143, Japan
| | - T Ohta
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - M Oka
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - J D Parker
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - C Rangacharyulu
- Department of Physics and Engineering Physics, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5E2, Canada
| | - S Y Ryu
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - T Sawada
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
- Physics Department, University of Michigan, Michigan 48109-1040, USA
| | - H Shimizu
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - E A Strokovsky
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
- Joint Institute for Nuclear Research, Dubna, Moscow Region 142281, Russia
| | - Y Sugaya
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - M Sumihama
- Department of Education, Gifu University, Gifu 501-1193, Japan
| | - T Tsunemi
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - M Uchida
- Department of Physics, Tokyo Institute of Technology, Tokyo 152-8551, Japan
| | - M Ungaro
- Department of Physics, University of Connecticut, Storrs, Connecticut 06269-3046, USA
| | - S Y Wang
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - M Yosoi
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| |
Collapse
|
66
|
Doi H, Harui S, Sugimoto A, Fujiwara M, Kamino K, Nakajima T, Ikuta S, Aihara T, Yamanaka N, Hishikawa Y. EP-1425: Clinical implications of a novel iron-containing fiducial marker in radiotherapy for liver tumors. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31734-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
67
|
Tanooka M, Tarutani K, Doi H, Suzuki H, Takada Y, Fujiwara M, Toda Y, Fujimoto H, Miyashita M, Okumura A, Kagawa K, Kamikonya N, Yamakado K. EP-1753: Sensing ability of EPID-based in vivo dosimetry for VMAT. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)32062-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
68
|
Doi H, Fujiwara M, Kitajima K, Tanooka M, Terada T, Noguchi K, Ishikura R, Kamikonya N, Yamakado K. EP-1119: Comparison between T staging and FDG-PET for predicting outcomes of maxillary sinus carcinoma. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31429-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
69
|
Tanaka C, Kanda M, Misawa K, Ito S, Ito Y, Mochizuki Y, Ishigure K, Yaguchi T, Teramoto J, Nakayama H, Kawase Y, Fujiwara M, Kodera Y. Nutritional recovery after open and laparoscopic distal gastrectomy for early gastric cancer: A prospective multicenter comparative trial (CCOG1204). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
70
|
Fujiwara M, masumoto N, Sasada S, Kadoya T, Okada M. Dedicated breast PET to predict pathological complete response after neoadjuvant chemotherapy for breast cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx364.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
71
|
Tanaka Y, Kanda M, Tanaka C, Kobayashi D, Tanaka H, Takami H, Hayashi M, Iwata N, Niwa Y, Yamada S, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y. Involvement of the immunoregulator MZB1 in progression of gastric cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
72
|
Nagamoto Y, Fujii Y, Morita Y, Ueda Y, Miyake Y, Yamane K, Fujiwara M, Mito S, Tamekiyo H, Okimoto T, Muraoka Y, Hayashi Y. P1720Clinical significance of the number of dissociated pulmonary vein activity following pulmonary vein isolation in patients undergoing atrial fibrillation ablation. Europace 2017. [DOI: 10.1093/ehjci/eux161.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
73
|
Mito S, Muraoka Y, Fujii Y, Ueda Y, Morita Y, Fujiwara M, Nagamoto Y, Hayashi Y. P1762His-Bundle Potential Inversion Predicts Adequate Placement of His-Bundle Pacing Lead. Europace 2017. [DOI: 10.1093/ehjci/eux161.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
74
|
Mito S, Muraoka Y, Fujii Y, Ueda Y, Morita Y, Fujiwara M, Nagamoto Y, Hayashi Y. 1164Early recurrence and long-term results of additional ganglionated plexi ablation for paroxysmal atrial fibrillation. Europace 2017. [DOI: 10.1093/ehjci/eux153.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
75
|
Mito S, Muraoka Y, Fujii Y, Ueda Y, Morita Y, Fujiwara M, Nagamoto Y, Hayashi Y. P1460Efficacy of ganglionated plexus ablation in patients with obstructive sleep apnea. Europace 2017. [DOI: 10.1093/ehjci/eux158.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
76
|
Motojima O, Yamada H, Komori A, Watanabe KY, Mutoh T, Takeiri Y, Ida K, Akiyama T, Asakura N, Ashikawa N, Chikaraishi H, Cooper WA, Emoto M, Fujita T, Fujiwara M, Funaba H, Goncharov P, Goto M, Hamada Y, Higashijima S, Hino T, Hoshino M, Ichimura M, Idei H, Ido T, Ikeda K, Imagawa S, Inagaki S, Isayama A, Isobe M, Itoh T, Itoh K, Kado S, Kalinina D, Kaneba T, Kaneko O, Kato D, Kato T, Kawahata K, Kawashima H, Kawazome H, Kobuchi T, Kondo K, Kubo S, Kumazawa R, Lyon JF, Maekawa R, Mase A, Masuzaki S, Mito T, Matsuoka K, Miura Y, Miyazawa J, More R, Morisaki T, Morita S, Murakami I, Murakami S, Mutoh S, Nagaoka K, Nagasaki K, Nagayama Y, Nakamura Y, Nakanishi H, Narihara K, Narushima Y, Nishimura H, Nishimura K, Nishiura M, Nishizawa A, Noda N, Notake T, Nozato H, Ohdachi S, Ohkubo K, Ohyabu N, Oyama N, Oka Y, Okada H, Osakabe M, Ozaki T, Peterson BJ, Sagara A, Saida T, Saito K, Sakakibara S, Sakamoto M, Sakamoto R, Sasao M, Sato K, Seki T, Shimozuma T, Shoji M, Sudo S, Takagi S, Takahashi Y, Takase Y, Takenaga H, Takeuchi N, Tamura N, Tanaka K, Tanaka M, Toi K, Takahata K, Tokuzawa T, Torii Y, Tsumori K, Watanabe F, Watanabe M, Watanabe T, Watari T, Yamada I, Yamada S, Yamaguchi T, Yamamoto S, Yamazaki K, Yanagi N, Yokoyama M, Yoshida N, Yoshimura S, Yoshimura Y, Yoshinuma M. Review on the Progress of the LHD Experiment. Fusion Science and Technology 2017. [DOI: 10.13182/fst04-a535] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- O. Motojima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Yamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Komori
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Y. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Mutoh
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Takeiri
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Ida
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Akiyama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Asakura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Ashikawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Chikaraishi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - W. A. Cooper
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Emoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Fujita
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Fujiwara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Funaba
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - P. Goncharov
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Goto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Hamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Higashijima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Hino
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Hoshino
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Ichimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Idei
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Ido
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Ikeda
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Imagawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Inagaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Isayama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Isobe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Itoh
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Itoh
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Kado
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - D. Kalinina
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Kaneba
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - O. Kaneko
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - D. Kato
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Kato
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Kawahata
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Kawashima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Kawazome
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Kobuchi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Kondo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Kubo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - R. Kumazawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - J. F. Lyon
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - R. Maekawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Mase
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Masuzaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Mito
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Matsuoka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Miura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - J. Miyazawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - R. More
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Morisaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Morita
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - I. Murakami
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Murakami
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Mutoh
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Nagaoka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Nagasaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Nagayama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Nakamura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Nakanishi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Narihara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Narushima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Nishimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Nishimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Nishiura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Nishizawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Noda
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Notake
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Nozato
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Ohdachi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Ohkubo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Ohyabu
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Oyama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Oka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Okada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Osakabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Ozaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - B. J. Peterson
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Sagara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Saida
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Saito
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Sakakibara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Sakamoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - R. Sakamoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Sasao
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Sato
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Seki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Shimozuma
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Shoji
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Sudo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Takagi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Takahashi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Takase
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Takenaga
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Takeuchi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Tamura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Tanaka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Tanaka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Toi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Takahata
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Tokuzawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Torii
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Tsumori
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - F. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Watari
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - I. Yamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Yamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Yamaguchi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Yamamoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Yamazaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Yanagi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Yokoyama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Yoshida
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Yoshimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Yoshimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Yoshinuma
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| |
Collapse
|
77
|
Sibson P, Erven C, Godfrey M, Miki S, Yamashita T, Fujiwara M, Sasaki M, Terai H, Tanner MG, Natarajan CM, Hadfield RH, O'Brien JL, Thompson MG. Chip-based quantum key distribution. Nat Commun 2017; 8:13984. [PMID: 28181489 PMCID: PMC5309763 DOI: 10.1038/ncomms13984] [Citation(s) in RCA: 156] [Impact Index Per Article: 22.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2016] [Accepted: 11/17/2016] [Indexed: 11/09/2022] Open
Abstract
Improvement in secure transmission of information is an urgent need for governments, corporations and individuals. Quantum key distribution (QKD) promises security based on the laws of physics and has rapidly grown from proof-of-concept to robust demonstrations and deployment of commercial systems. Despite these advances, QKD has not been widely adopted, and large-scale deployment will likely require chip-based devices for improved performance, miniaturization and enhanced functionality. Here we report low error rate, GHz clocked QKD operation of an indium phosphide transmitter chip and a silicon oxynitride receiver chip—monolithically integrated devices using components and manufacturing processes from the telecommunications industry. We use the reconfigurability of these devices to demonstrate three prominent QKD protocols—BB84, Coherent One Way and Differential Phase Shift—with performance comparable to state-of-the-art. These devices, when combined with integrated single photon detectors, pave the way for successfully integrating QKD into future telecommunications networks. Quantum key distribution has not been widely adopted in part due to technical hurdles preventing it being fully integrated in classical communication networks. Here the authors report quantum key distribution between two photonic chips manufactured with state-of-the-art telecoms industry processes.
Collapse
Affiliation(s)
- P Sibson
- Centre for Quantum Photonics, H. H. Wills Physics Laboratory and Department of Electrical and Electronic Engineering, University of Bristol, Merchant Venturers Building, Woodland Road, Bristol BS8 1UB, UK
| | - C Erven
- Centre for Quantum Photonics, H. H. Wills Physics Laboratory and Department of Electrical and Electronic Engineering, University of Bristol, Merchant Venturers Building, Woodland Road, Bristol BS8 1UB, UK
| | - M Godfrey
- Centre for Quantum Photonics, H. H. Wills Physics Laboratory and Department of Electrical and Electronic Engineering, University of Bristol, Merchant Venturers Building, Woodland Road, Bristol BS8 1UB, UK
| | - S Miki
- National Institute of Information and Communications Technology (NICT), 588-2 Iwaoka, Kobe 651-2492, Japan
| | - T Yamashita
- National Institute of Information and Communications Technology (NICT), 588-2 Iwaoka, Kobe 651-2492, Japan
| | - M Fujiwara
- National Institute of Information and Communications Technology (NICT), 4-2-1 Nukui-Kitamachi, Koganei, Tokyo 184-8795, Japan
| | - M Sasaki
- National Institute of Information and Communications Technology (NICT), 4-2-1 Nukui-Kitamachi, Koganei, Tokyo 184-8795, Japan
| | - H Terai
- National Institute of Information and Communications Technology (NICT), 588-2 Iwaoka, Kobe 651-2492, Japan
| | - M G Tanner
- School of Engineering, University of Glasgow, Glasgow G12 8QQ, UK
| | - C M Natarajan
- School of Engineering, University of Glasgow, Glasgow G12 8QQ, UK
| | - R H Hadfield
- School of Engineering, University of Glasgow, Glasgow G12 8QQ, UK
| | - J L O'Brien
- Centre for Quantum Photonics, H. H. Wills Physics Laboratory and Department of Electrical and Electronic Engineering, University of Bristol, Merchant Venturers Building, Woodland Road, Bristol BS8 1UB, UK
| | - M G Thompson
- Centre for Quantum Photonics, H. H. Wills Physics Laboratory and Department of Electrical and Electronic Engineering, University of Bristol, Merchant Venturers Building, Woodland Road, Bristol BS8 1UB, UK
| |
Collapse
|
78
|
Doi H, Matsumoto S, Odawara S, Shikata T, Tanooka M, Kitajima K, Takada Y, Fujiwara M, Tsujimura T, Kamikonya N, Hirota S. Pravastatin Reduces Radiation-Induced Damage to Normal Tissues. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.2031] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
79
|
Oya H, Kanda M, Koike M, Iwata N, Niwa Y, Shimizu D, Takami H, Sueoka S, Hashimoto R, Ezaka K, Nomoto S, Yamada S, Fujii T, Nakayama G, Sugimoto H, Fujiwara M, Kodera Y. Detection of serum melanoma-associated antigen D4 in patients with squamous cell carcinoma of the esophagus. Dis Esophagus 2016; 29:663-9. [PMID: 25951896 DOI: 10.1111/dote.12373] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Despite improvements in surgical techniques, perioperative management, and multidisciplinary therapy, treatment outcomes of patients with esophageal squamous cell carcinoma (ESCC) remain poor. Therefore, development of novel molecular biomarkers, which either predict patient survival or become therapeutic targets, is urgently required. In the present study, to facilitate early detection of ESCC and predict its clinical course, we investigated the relationship of the serum level of melanoma-associated antigen (MAGE)-D4 to patients' clinicopathological characteristics. Using quantitative real-time reverse transcription-polymerase chain reaction and enzyme-linked immunosorbent assays, we determined the levels of MAGE-D4 mRNA and protein in cell lysates and conditioned medium of cultures, respectively, of nine ESCC cell lines. Further, we determined MAGE-D4 levels in serum samples collected from 44 patients with ESCC who underwent radical esophagectomy without neoadjuvant therapy as well as from 40 healthy volunteers. Samples of conditioned medium and cell lysates contained comparable levels of MAGE-D4 that correlated closely with the levels of MAGE-D4 mRNA. Preoperative MAGE-D4 levels in the sera of 44 patients with ESCC, which varied from 0 to 2,354 pg/mL (314 ± 505 pg/mL, mean ± standard deviation), were significantly higher compared with those of healthy volunteers. By setting the cutoff at the highest value for healthy volunteers (50 pg/mL), the MAGE-D4-positive group of patients was more likely to have shorter disease-specific and disease-free survival compared with those of the MAGE-D4-negative group, although the differences were not statistically significant. Our results indicate that the elevation of preoperative serum MAGE-D4 levels in some patients with ESCC was possibly caused by excess production of MAGE-D4 by tumor cells followed by its release into the circulation. Clinical implications of serum MAGE-D4 levels should be validated in a large population of patients with ESCC.
Collapse
Affiliation(s)
- H Oya
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Kanda
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Koike
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - N Iwata
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Y Niwa
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - D Shimizu
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - H Takami
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - S Sueoka
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - R Hashimoto
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - K Ezaka
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - S Nomoto
- Department of Surgery, Aichi-Gakuin University School of Dentistry, Nagoya, Japan
| | - S Yamada
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Fujii
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - G Nakayama
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - H Sugimoto
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Fujiwara
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Y Kodera
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
80
|
Niwa Y, Koike M, Fujimoto Y, Oya H, Iwata N, Nishio N, Hiramatsu M, Kanda M, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Nomoto S, Fujiwara M, Kodera Y. Salvage pharyngolaryngectomy with total esophagectomy following definitive chemoradiotherapy. Dis Esophagus 2016; 29:598-602. [PMID: 26338205 DOI: 10.1111/dote.12362] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Historically, total pharyngolaryngectomy with total esophagectomy has been the standard radical surgical treatment for synchronous cancer of the thoracoabdominal esophagus and pharyngolaryngeal region, and for cancer of the cervical esophagus that has invaded as far as the thoracic esophagus. Although definitive chemoradiotherapy that enables preservation of the larynx has often been the first choice of treatment for cancers involving the cervical esophagus, total pharyngolaryngectomy with total esophagectomy is required as a salvage therapy for cases involving failure of complete remission or locoregional recurrence after chemoradiotherapy. However, salvage esophageal surgery after definitive high-dose chemoradiotherapy is generally associated with high morbidity and mortality. The aim of this study was to examine the short-term outcome of salvage total pharyngolaryngectomy with total esophagectomy. From 2001 to 2014, nine patients underwent salvage total pharyngolaryngectomy with total esophagectomy at the Department of Gastroenterological Surgery, Nagoya University. The mortality and morbidity rates were high at 22% and 89%, respectively. Four patients (44%) developed tracheal necrosis, which in two patients eventually led to lethal hemorrhage. Salvage total pharyngolaryngectomy with total esophagectomy is an uncommon and highly demanding surgical procedure that should be carefully planned and conducted in selected centers of excellence. Measures must be taken to preserve the tracheal blood supply, thus avoiding fatal complications.
Collapse
Affiliation(s)
- Y Niwa
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Koike
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Y Fujimoto
- Department of Otorhinolaryngology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - H Oya
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - N Iwata
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - N Nishio
- Department of Otorhinolaryngology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Hiramatsu
- Department of Otorhinolaryngology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Kanda
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - D Kobayashi
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - C Tanaka
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - S Yamada
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Fujii
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - G Nakayama
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - H Sugimoto
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - S Nomoto
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Fujiwara
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Y Kodera
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
81
|
Fujiwara M, Ijichi K, Tokuhisa K, Katsuura K, Wang GYS, Uemura D, Shigeta S, Konno K, Yokota T, Baba M. Ingenol Derivatives are Highly Potent and Selective Inhibitors of HIV Replication in Vitro. ACTA ACUST UNITED AC 2016. [DOI: 10.1177/095632029600700502] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Ingenol 3,5,20-triacetate has recently been identified as a highly potent and selective inhibitor of HIV replication in vitro. To evaluate the potential of ingenol derivatives as anti-HIV agents, several ingenol derivatives have been synthesized and investigated for their anti-HIV activities, structure-activity relationships, and possible mechanisms of action. Among the ingenol derivatives, 13-hydroxyingenol-3-(2,3-dimethylbutanoate)-13-dodecanoate (RD4-2138) proved to be a highly potent and selective inhibitor of HIV replication. Its 50% effective concentration for viral replication in MT-4 cells was 0.07-0.5 nM depending on viral strains, including HIV-2. This concentration was approximately 105-fold lower than its cytotoxic threshold. RD4-2138 was also inhibitory to the syncytium formation induced by cocultivation of Molt-4 cells with Molt-4/IIIB cells (Molt-4 cells chronically infected with HIV-1). Some correlation was observed with the ingenol derivatives between their inhibitory effects on HTLV-IIIB replication and surface CD4 expression in MT-4 cells, suggesting that the mechanism of inhibition is in part attributed to the inhibition of virus adsorption through down-regulation of CD4 molecules in the host cells. However, such correlation was not identified between the inhibition of HTLV-IIIB and the activation of protein kinase C. Thus, they might have a potential as effective anti-HIV agents when toxicity in vivo could be elucidated.
Collapse
Affiliation(s)
- M. Fujiwara
- Rational Drug Design Laboratories, Matsukawa-machi, Fukushima 960-12, Japan
| | - K. Ijichi
- Rational Drug Design Laboratories, Matsukawa-machi, Fukushima 960-12, Japan
| | - K. Tokuhisa
- Tokyo Research Laboratory, Tosoh Co, Ltd, Ayase, Kanagawa 252, Japan
| | - K. Katsuura
- Tokyo Research Laboratory, Tosoh Co, Ltd, Ayase, Kanagawa 252, Japan
| | - G.-Y.-S. Wang
- Faculty of Liberal Arts, Shizuoka University, Ohya, Shizuoka 422, Japan
| | - D. Uemura
- Faculty of Liberal Arts, Shizuoka University, Ohya, Shizuoka 422, Japan
- Sagami Chemical Research Centre, Sagamihara, Kanagawa 229, Japan
| | - S. Shigeta
- Department of Microbiology, Fukushima Medical College, Hikarigaoka, Fukushima 960-12, Japan
| | - K. Konno
- Rational Drug Design Laboratories, Matsukawa-machi, Fukushima 960-12, Japan
| | - T. Yokota
- Rational Drug Design Laboratories, Matsukawa-machi, Fukushima 960-12, Japan
| | - M. Baba
- Division of Human Retroviruses, Centre for Chronic Viral Diseases, Faculty of Medicine, Kagoshima University, Sakuragaoka, Kagoshima 890, Japan
| |
Collapse
|
82
|
Ryu SY, Ahn JK, Nakano T, Ahn DS, Ajimura S, Akimune H, Asano Y, Chang WC, Chen JY, Daté S, Ejiri H, Fujimura H, Fujiwara M, Fukui S, Hasegawa S, Hicks K, Horie K, Hotta T, Hwang SH, Imai K, Ishikawa T, Iwata T, Kato Y, Kawai H, Kino K, Kohri H, Kon Y, Kumagai N, Lin PJ, Maeda Y, Makino S, Matsuda T, Matsuoka N, Mibe T, Miyabe M, Miyachi M, Morino Y, Muramatsu N, Murayama R, Nakatsugawa Y, Nam SI, Niiyama M, Nomachi M, Ohashi Y, Ohkuma H, Ohta T, Ooba T, Oshuev DS, Parker JD, Rangacharyulu C, Sakaguchi A, Sawada T, Shagin PM, Shiino Y, Shimizu H, Strokovsky EA, Sugaya Y, Sumihama M, Tokiyasu AO, Toi Y, Toyokawa H, Tsunemi T, Uchida M, Ungaro M, Wakai A, Wang CW, Wang SC, Yonehara K, Yorita T, Yoshimura M, Yosoi M, Zegers RGT. Interference Effect between ϕ and Λ(1520) Production Channels in the γp→K^{+}K^{-}p Reaction near Threshold. Phys Rev Lett 2016; 116:232001. [PMID: 27341225 DOI: 10.1103/physrevlett.116.232001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/02/2016] [Indexed: 06/06/2023]
Abstract
The ϕ-Λ(1520) interference effect in the γp→K^{+}K^{-}p reaction has been measured for the first time in the energy range from 1.673 to 2.173 GeV. The relative phases between ϕ and Λ(1520) production amplitudes were obtained in the kinematic region where the two resonances overlap. The measurement results support strong constructive interference when K^{+}K^{-} pairs are observed at forward angles but destructive interference for proton emission at forward angles. Furthermore, the observed interference effect does not account for the sqrt[s]=2.1 GeV bump structure in forward differential cross sections for ϕ photoproduction. This fact suggests possible exotic structures such as a hidden-strangeness pentaquark state, a new Pomeron exchange, or rescattering processes via other hyperon states.
Collapse
Affiliation(s)
- S Y Ryu
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - J K Ahn
- Department of Physics, Korea University, Seoul 02841, Republic of Korea
| | - T Nakano
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - D S Ahn
- RIKEN, The Institute of Physical and Chemical Research, Wako, Saitama 351-0198, Japan
| | - S Ajimura
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - H Akimune
- Department of Physics, Konan University, Kobe, Hyogo 658-8501, Japan
| | - Y Asano
- XFEL Project Head Office, RIKEN, Sayo, Hyogo 679-5143, Japan
| | - W C Chang
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - J Y Chen
- Light Source Division, National Synchrotron Radiation Research Center, Hsinchu 30076, Taiwan
| | - S Daté
- Japan Synchrotron Radiation Research Institute, Sayo, Hyogo 679-5143, Japan
| | - H Ejiri
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - H Fujimura
- Wakayama Medical College, Wakayama 641-8509, Japan
| | - M Fujiwara
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - S Fukui
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - S Hasegawa
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - K Hicks
- Department of Physics and Astronomy, Ohio University, Athens, Ohio 45701, USA
| | - K Horie
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - T Hotta
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - S H Hwang
- Korea Research Institute of Standards and Science (KRISS), Daejeon 34113, Republic of Korea
| | - K Imai
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195, Japan
| | - T Ishikawa
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - T Iwata
- Department of Physics, Yamagata University, Yamagata 990-8560, Japan
| | - Y Kato
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya, Aichi 464-8602, Japan
| | - H Kawai
- Department of Physics, Chiba University, Chiba 263-8522, Japan
| | - K Kino
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - H Kohri
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - Y Kon
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - N Kumagai
- Japan Synchrotron Radiation Research Institute, Sayo, Hyogo 679-5143, Japan
| | - P J Lin
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - Y Maeda
- Proton Therapy Center, Fukui Prefectural Hospital, Fukui 910-8526, Japan
| | - S Makino
- Wakayama Medical College, Wakayama 641-8509, Japan
| | - T Matsuda
- Department of Applied Physics, Miyazaki University, Miyazaki 889-2192, Japan
| | - N Matsuoka
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - T Mibe
- High Energy Accelerator Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - M Miyabe
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - M Miyachi
- Department of Physics, Tokyo Institute of Technology, Tokyo 152-8551, Japan
| | - Y Morino
- High Energy Accelerator Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - N Muramatsu
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - R Murayama
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - Y Nakatsugawa
- High Energy Accelerator Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - S I Nam
- Department of Physics, Pukyong National University, Busan 48513, Republic of Korea
| | - M Niiyama
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - M Nomachi
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - Y Ohashi
- Japan Synchrotron Radiation Research Institute, Sayo, Hyogo 679-5143, Japan
| | - H Ohkuma
- Japan Synchrotron Radiation Research Institute, Sayo, Hyogo 679-5143, Japan
| | - T Ohta
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - T Ooba
- Department of Physics, Chiba University, Chiba 263-8522, Japan
| | - D S Oshuev
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - J D Parker
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - C Rangacharyulu
- Department of Physics and Engineering Physics, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5E2, Canada
| | - A Sakaguchi
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - T Sawada
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - P M Shagin
- School of Physics and Astronomy, University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - Y Shiino
- Department of Physics, Chiba University, Chiba 263-8522, Japan
| | - H Shimizu
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - E A Strokovsky
- Joint Institute for Nuclear Research, Dubna, Moscow Region, 142281, Russia
| | - Y Sugaya
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - M Sumihama
- Department of Education, Gifu University, Gifu 501-1193, Japan
| | - A O Tokiyasu
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - Y Toi
- Department of Applied Physics, Miyazaki University, Miyazaki 889-2192, Japan
| | - H Toyokawa
- Japan Synchrotron Radiation Research Institute, Sayo, Hyogo 679-5143, Japan
| | - T Tsunemi
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - M Uchida
- Department of Physics, Tokyo Institute of Technology, Tokyo 152-8551, Japan
| | - M Ungaro
- Department of Physics, University of Connecticut, Storrs, Connecticut 06269-3046, USA
| | - A Wakai
- Akita Research Institute of Brain and Blood Vessels, Akita 010-0874, Japan
| | - C W Wang
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - S C Wang
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - K Yonehara
- Department of Physics, Konan University, Kobe, Hyogo 658-8501, Japan
| | - T Yorita
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - M Yoshimura
- Institute for Protein Research, Osaka University, Suita, Osaka 565-0871, Japan
| | - M Yosoi
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - R G T Zegers
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| |
Collapse
|
83
|
Numao N, Ito M, Matsuoka Y, Yoshida S, Fujiwara M, Nakamura Y, Waseda Y, Moriyama S, Nakayama T, Tanaka H, Inoue M, Kawamura N, Yokoyama M, Ishioka J, Saito K, Fujii Y, Kihara K. MP16-18 OPTIMAL COMBINATION OF MRI-TARGETED BIOPSY AND SYSTEMATIC BIOPSY FOR MEN WITH SUSPICION OF PROSTATE CANCER. J Urol 2016. [DOI: 10.1016/j.juro.2016.02.2583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
84
|
Fujiwara M, Inoue M, Yokoyama M, Kijima T, Nakayama T, Ito M, Yoshida S, Ishioka J, Matsuoka Y, Numao N, Saito K, Fujii Y, Kihara K. MP24-18 FEASIBILITY OF NON-USE OF ANTIMICROBIAL PROPHYLAXIS IN MINIMALLY INVASIVE CLEAN SURGERY FOR RENAL OR ADRENAL TUMORS: A PROSPECTIVE STUDY OF 668 CASES. J Urol 2016. [DOI: 10.1016/j.juro.2016.02.774] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
85
|
Nakada Y, Fujiwara M, Yakami M, Yokoyama T, Shirayama A, Yamamoto H, Nabatame K, Obara S, Akahane K, Blyth BJ, Miyazaki O, Date H, Yagi K, Hoshioka A, Shimada Y. Optimised paediatric CT dose at a tertiary children's hospital in Japan: a 4-y single-centre analysis. Radiat Prot Dosimetry 2016; 168:61-71. [PMID: 25669653 DOI: 10.1093/rpd/ncv004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/16/2014] [Accepted: 01/09/2015] [Indexed: 06/04/2023]
Abstract
Since diagnostic reference levels (DRLs) for children are not currently established in Japan, the authors determined local DRLs for the full range of paediatric CT examinations in a single tertiary care children's hospital. A retrospective review of 4801 CT performance records for paediatric patients (<15 y old) who had undergone CT examinations from 2008 to 2011 was conducted. The most frequent examinations were of the head (52 %), followed by cardiac (15 %), temporal bone (9 %), abdomen (7 %), chest (6 %) and others (11 %). Approximately one-third of children received two or more CT scans. The authors' investigation showed that mean CTDIvol and DLP for head, chest and abdomen increased as a function of age. Benchmarking of the results showed that CTDIvol, DLP and effective dose for chest and abdomen examinations in this hospital were below average, whereas those for the head tended to be at or slightly above average of established DRL values from five countries. The results suggest that CT examinations as performed in a tertiary children's hospital in Japan are well optimised.
Collapse
Affiliation(s)
- Y Nakada
- National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba, Japan
| | - M Fujiwara
- Chiba Children's Hospital, 579-1 Heta, Midori-ku, Chiba, Japan
| | - M Yakami
- Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, 54 Shougoinkawahara, Sakyo-ku, Kyoto, Japan
| | - T Yokoyama
- Chiba Children's Hospital, 579-1 Heta, Midori-ku, Chiba, Japan
| | - A Shirayama
- Chiba Children's Hospital, 579-1 Heta, Midori-ku, Chiba, Japan
| | - H Yamamoto
- National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba, Japan
| | - K Nabatame
- National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba, Japan
| | - S Obara
- National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba, Japan
| | - K Akahane
- National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba, Japan
| | - B J Blyth
- National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba, Japan
| | - O Miyazaki
- National Center for Child Health and Development, 2-10-1 Ookura, Setagaya-ku, Tokyo, Japan
| | - H Date
- Chiba Children's Hospital, 579-1 Heta, Midori-ku, Chiba, Japan
| | - K Yagi
- Tokyo Metropolitan University, 7-2-10 Higashiogu, Arakawa-ku, Tokyo, Japan
| | - A Hoshioka
- Chiba Children's Hospital, 579-1 Heta, Midori-ku, Chiba, Japan
| | - Y Shimada
- National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba, Japan
| |
Collapse
|
86
|
Kai M, Fujiwara M, Miyoshi M, Nishiyama Y, Aoyama-Ishikawa M, Maeshige N, Inoue T, Uemura M, Yamashita H, Koga Y, Usami M. SUN-PP039: Up-Regulation of Hepatic Ppara and Pparγ in Endotoxemic Rats by Feeding Lard-Rich High-Fat Diet for 12 Weeks. Clin Nutr 2015. [DOI: 10.1016/s0261-5614(15)30190-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
87
|
Kobayashi D, Tanaka C, Kanda M, Iwata N, Yamada S, Nakayama G, Fujii T, Sugimoto H, Koike M, Fujiwara M, Kodera Y. MON-PP073: Impact of Body Weight Loss after Gastrectomy on the Postoperative S-1 Chemotherapy for Gastric Cancer. Clin Nutr 2015. [DOI: 10.1016/s0261-5614(15)30505-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
88
|
Kosaka K, Tanooka M, Inoue H, Tarutani K, Fujiwara M, Niwa Y, Takada Y, Doi H, Odawara S, Suzuki H, Kamikonya N, Hirota S. 634 Correlation analysis between pre-treatment verification precision and plan complexity or machine parameters using log files for VMAT delivery. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30370-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
89
|
Doi H, Beppu N, Kato T, Tanooka M, Kengo K, Tarutani K, Suzuki H, Odawara S, Niwa Y, Takada Y, Fujiwara M, Noda M, Tomita N, Kamikonya N, Hirota S. 2035 Diffusion-weighted magnetic resonance imaging for the prediction of the tumor response to neoadjuvant chemoradiotherapy using irinotecan plus S-1 for rectal cancer. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30958-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
90
|
Iwai T, Terasaki H, Aoyama A, Izumi Y, Umeda M, Heima S, Inoue Y, Fujiwara M. Arterial and Venous Invasion after Intraluminal Injection of Oral Bacteria (P. gingivalis) in a Rat Model shows Buerger Disease Pathology. Eur J Vasc Endovasc Surg 2015. [DOI: 10.1016/j.ejvs.2015.03.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
91
|
Dixon AR, Dynes JF, Lucamarini M, Fröhlich B, Sharpe AW, Plews A, Tam S, Yuan ZL, Tanizawa Y, Sato H, Kawamura S, Fujiwara M, Sasaki M, Shields AJ. High speed prototype quantum key distribution system and long term field trial. Opt Express 2015; 23:7583-7592. [PMID: 25837096 DOI: 10.1364/oe.23.007583] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Securing information in communication networks is an important challenge in today's world. Quantum Key Distribution (QKD) can provide unique capabilities towards achieving this security, allowing intrusions to be detected and information leakage avoided. We report here a record high bit rate prototype QKD system providing a total of 878 Gbit of secure key data over a 34 day period corresponding to a sustained key rate of around 300 kbit/s. The system was deployed over a standard 45 km link of an installed metropolitan telecommunication fibre network in central Tokyo. The prototype QKD system is compact, robust and automatically stabilised, enabling key distribution during diverse weather conditions. The security analysis includes an efficient protocol, finite key size effects and decoy states, with a quantified key failure probability of ε = 10⁻¹⁰.
Collapse
|
92
|
Yasui N, Kawamoto H, Fujiwara M, Aihara Y, Ogawa C, Hosono A, Suzuki S. High-dose chemotherapy for high-risk retinoblastoma: clinical course and outcome of 14 cases in the National Cancer Center, Japan. Bone Marrow Transplant 2014; 50:221-4. [PMID: 25437249 DOI: 10.1038/bmt.2014.256] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2014] [Revised: 08/26/2014] [Accepted: 09/12/2014] [Indexed: 11/09/2022]
Abstract
The prognosis of high-risk retinoblastoma (RB) with extraocular disease, relapse, or invasion of the cut end of the optic nerve is extremely poor. Following the discontinuation of thiotepa production in Japan, BU- and melphalan (Mel)-based regimens have been used, followed by the standard treatment for neuroblastoma. This study retrospectively analyzed 14 high-risk RB patients who underwent high-dose chemotherapy (HDC) and hematopoietic SCT; 8 received a BU/Mel conditioning regimen and 6 received other regimens. The disease status at HDC was relapse in 8 patients and extraocular involvement in 5. All patients received peripheral blood stem cell infusion >1.5 × 10(6)/kg. Engraftment occurred within a median of 11 days (BU/Mel: 10-13, others: 9-13). Primary toxicities included mucositis (⩾grade 3) in 9 patients (4 with BU/Mel, 5 with others). Veno-occlusive disease (VOD) occurred in two 1-year-old patients in the BU/Mel group. There were no treatment-related deaths. Of 4 (2 with BU/Mel, 2 with others) patients with central nervous system (CNS) relapse after HDC, 3 died. In conclusion, the BU/Mel regimen may be feasible for high-risk RB under careful monitoring for VOD, particularly in younger patients. CNS relapse associated with a lethal prognosis occurred after all regimens; therefore, further evaluation of HDC efficacy for high-risk RB is required.
Collapse
Affiliation(s)
- N Yasui
- Division of Pediatric Oncology, National Cancer Center, Tokyo, Japan
| | - H Kawamoto
- Division of Pediatric Oncology, National Cancer Center, Tokyo, Japan
| | - M Fujiwara
- Department of Ophthalmic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Y Aihara
- Department of Ophthalmic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - C Ogawa
- Division of Pediatric Oncology, National Cancer Center, Tokyo, Japan
| | - A Hosono
- Division of Pediatric Oncology, National Cancer Center Hospital East, Tokya, Japan
| | - S Suzuki
- Department of Ophthalmic Oncology, National Cancer Center Hospital, Tokyo, Japan
| |
Collapse
|
93
|
Kanda M, Shimizu D, Sugimoto H, Oya H, Hibino S, Takami H, Hashimoto R, Okamura Y, Yamada S, Fujii T, Nakayama G, Koike M, Nomoto S, Fujiwara M, Kodera Y. B-Cell Translocation Gene 1 Serves As a Novel Prognostic Indicator of Hepatocellular Carcinoma. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu334.120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
94
|
Miyoshi M, Fujiwara M, Aoyama-Ishikawa M, Nishiokada A, Kai M, Nishiyama Y, Maeshige N, Usami M. PP079-SUN: Oral Administration of Tributyrin Attenuates Lipopolysaccharide-Induced Intestinal Injury in Rat. Clin Nutr 2014. [DOI: 10.1016/s0261-5614(14)50121-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
95
|
Shimizu D, Kanda M, Sugimoto H, Oya H, Takami H, Hibino S, Hashimoto R, Okamura Y, Yamada S, Fujii T, Nakayama G, Koike M, Nomoto S, Fujiwara M, Kodera Y. Identification of Intragenic Methylation in the Tusc1 Gene As a Novel Prognostic Marker of Hepatocellular Carcinoma. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu334.121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
96
|
Nishiokada A, Miyoshi M, Fujiwara M, Aoyama-Ishikawa M, Nishiyama Y, Kai M, Maeshige N, Takahashi M, Hamada Y, Usami Y, Arita M, Usami M. PP010-SUN: Changes of Hepatic Lipid Mediators Associated with Intake of High-Fat Diet for 12 Weeks in Endotoxemic Rats using LC-ESI-MS/MS. Clin Nutr 2014. [DOI: 10.1016/s0261-5614(14)50052-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
97
|
Odawara S, Doi H, Tsujimura T, Shikata T, Suzuki H, Kosaka K, Inoue H, Tanooka M, Takada Y, Niwa Y, Fujiwara M, Kamikonya N, Hirota S. Polaprezinc Protects Intestinal Epithelium From Radiation-Induced Damage in Mice. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.2263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
98
|
Muroi C, Fujioka M, Mishima K, Irie K, Fujimura Y, Nakano T, Fandino J, Keller E, Iwasaki K, Fujiwara M. Effect of ADAMTS-13 on cerebrovascular microthrombosis and neuronal injury after experimental subarachnoid hemorrhage. J Thromb Haemost 2014; 12:505-14. [PMID: 24476338 DOI: 10.1111/jth.12511] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2013] [Accepted: 12/17/2013] [Indexed: 11/30/2022]
Abstract
BACKGROUND Microthrombosis and reactive inflammation contribute to neuronal injury after subarachnoid hemorrhage (SAH). ADAMTS-13 cleaves von Willebrand factor multimers, and inhibits thrombus formation and, seemingly, inflammatory reactions. OBJECTIVE To investigate the effect of ADAMTS-13 in experimental SAH. METHODS A total of 100 male C57/BL6 mice were randomly assigned to four groups: sham (n = 15), SAH (n = 27), vehicle (n = 25), and ADAMTS-13 (n = 23; 100 μL per 10 g of body weight of 100 μg of ADAMTS-13 per 1 mL of 0.9% NaCl; 20 min after SAH). Neurologic performance was assessed on days 1 and 2 after SAH. Animals were killed on day 2. The amounts of subarachnoid blood, microthrombi, apoptosis and degenerative neurons were compared. The degree of neuronal inflammation and vasospasm was also compared. In five mice each (SAH and ADAMTS-13 groups), bleeding time was assessed 2 h after SAH. RESULTS Systemic administration of ADAMTS-13 achieved significant amelioration of microthrombosis and improvement in neurologic performance. ADAMTS-13 reduced the amount of apoptotic and degenerative neurons. A tendency for decreased neuronal inflammation was observed. ADAMTS-13 did not show any significant effect on vasospasm. The degree of systemic inflammation was not changed by ADAMTS-13 administration. ADAMTS-13 neither increased the amount of subarachnoid blood nor prolonged the bleeding time. CONCLUSIONS ADAMTS-13 may reduce neuronal injury after SAH by reducing microthrombosis formation and neuronal inflammation, thereby providing a new option for mitigating the severity of neuronal injury after SAH.
Collapse
Affiliation(s)
- C Muroi
- Department of Neuropharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan; Institute of Aging and Brain Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan; Department of Neurosurgery, Kantonsspital Aarau, Aarau, Switzerland; Neurocritical Care Unit, Department of Neurosurgery, University Hospital Zurich, Zurich, Switzerland
| | | | | | | | | | | | | | | | | | | |
Collapse
|
99
|
Kakinoki K, Okano K, Oshima M, Suto H, Kashiwagi H, Yamamoto N, Akamoto S, Fujiwara M, Yachida S, Takama T, Hagiike M, Usuki H, Kamata H, Masaki T, Suzuki Y. A novel triple secured technique for pancreatic reconstruction following pancreaticoduodenectomy for a soft pancreas. Hepatogastroenterology 2014; 61:469-474. [PMID: 24901164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
BACKGROUND/AIMS Soft pancreases are susceptible to developing pancreatic fistula following pancreaticoduodenectomy. To reduce the incidence of pancreatic fistula after pancreaticoduodenectomy in patients with a soft pancreas, we developed a triple secured technique. In this study, we describe the details of this technique and also report on the postoperative outcomes. METHODOLOGY The triple secured technique employed an ultrasonic dissector for pancreatic transection with skeletonizing and ligating of the small pancreatic branch ducts, duct-invagination or duct-to-mucosa anastomosis for main pancreatic duct management, and, finally, four large stitches between the pancreatic stump parenchyma and the jejunal seromuscular layer to prevent minor pancreatic leakage. A total of 28 consecutive patients with a soft pancreas who underwent pancreaticoduodenectomy using our technique were included in this study. RESULTS Postopetrative complications occurred in 16 patients. Grade B pancreatic fistula developed in 6 patients. However, no grade C pancreatic fistula occurred in this series. Neither any reoperation nor in-hospital mortality was observed in this series. CONCLUSIONS Our triple secured technique after pancreaticoduodenectomy was feasible and safe, with an acceptable rate of grade B pancreatic fistula and no grade C pancreatic fistula for patients with a soft pancreas.
Collapse
|
100
|
Kobayashi D, Iwata N, Kanda M, Tanaka C, Yamada S, Nakayama G, Fujii T, Sugimoto H, Koike M, Nomoto S, Fujiwara M, Kodera Y. Treatment Strategy against Gastric Cancer with Peritoneal Metastasis in Its Early Developing Phase. J Surg Res 2014. [DOI: 10.1016/j.jss.2013.11.896] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|